Market Overview

MediciNova Met With FDA Monday for End-of-Phase 2 for MN-221 for the Treatment of Acute Exacerbations of Asthma


MediciNova (NASDAQ: MNOV) today announced that it conducted an End-of-Phase 2 meeting pertaining to the development of MN-221 for the treatment of acute exacerbations of asthma with the United States Food and Drug Administration (FDA) earlier today.

MN-221 is a novel, highly selective beta(2)-adrenergic receptor agonist in development for the treatment of acute exacerbations of asthma and COPD. An acute asthma or COPD exacerbation is defined as a long-lasting and severe episode that is not responsive to the standard bronchodilator or corticosteroid therapy. Patients with an asthma/COPD exacerbation typically go to the emergency room (ER) for treatment. If treatment in the ER is not successful, the patient may be admitted to the hospital.

See full press release

Posted-In: News Guidance Management


Related Articles (MNOV)

View Comments and Join the Discussion!

Partner Center